Last reviewed · How we verify
F 18 T807
At a glance
| Generic name | F 18 T807 |
|---|---|
| Also known as | 18F-AV-1451 |
| Sponsor | Tammie L. S. Benzinger, MD, PhD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)
- F 18 T807 Tau PET Imaging of Alzheimer's Disease
- Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.
- F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD) (PHASE2)
- A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease (PHASE1)
- Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans
- F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)
- Exploratory Evaluation of Flortaucipir Injection in Healthy Volunteers and Cognitively Impaired Subjects (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |